Biologics in the treatment of primary inflammatory myositis
- 31 July 2007
- journal article
- editorial
- Published by Elsevier BV in Joint Bone Spine
- Vol. 74 (4), 316-318
- https://doi.org/10.1016/j.jbspin.2006.11.013
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Treatment of early and refractory dermatomyositis with infliximab: a report of two casesClinical Rheumatology, 2006
- Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximabRheumatology, 2005
- Advanced refractory polymyositis responding to infliximabRheumatology, 2005
- Treatment of Dermatomyositis and Polymyositis with Anti-Tumor Necrosis Factor-α: Long-Term Follow-UpEuropean Neurology, 2004
- Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximabRheumatology, 2004
- Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alphaRheumatology, 2004
- Refractory polymyositis responding to infliximab: extended follow-upRheumatology, 2004
- Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary ObservationsEuropean Neurology, 2003
- Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximabRheumatology, 2002
- Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.Clinical Rheumatology, 2000